| Similar Articles |
|---|
 |
The Motley Fool
July 23, 2010
Brian Orelli |
Eli Lilly Looks Great Today, but I'm Concerned About Tomorrow Eli Lilly is firing on all cylinders, but is there a blowout in its future?   |
The Motley Fool
April 20, 2009
Brian Orelli |
A Cheer and a Boo for Eli Lilly Cost-cutting is nice, but it doesn't slow down the drive toward the patent cliff. Lilly needs to be on the lookout for other partnerships to fill in the upcoming revenue holes. |
The Motley Fool
December 12, 2008
Brian Orelli |
A Long-Term Play for Your Port Long-term prospects look better than the near term ones for Eli Lilly and its investors. |
The Motley Fool
October 21, 2010
Brian Orelli |
Nice Earnings, Eli Lilly, but ... Eli Lilly trounced analysts' earnings estimates today, but investors sighed -- and for good reason. |
The Motley Fool
April 19, 2011
Brian Orelli |
See You on the Other Side of the Cliff Lilly beats, but there's still a lot of unknowns. Can the company continue the trend through the patent cliff? |
The Motley Fool
December 10, 2009
Brian Orelli |
A Tale of Two Lillys It was the best of times, it was the worst of times. Dickens could have been talking about Eli Lilly which has a tale of two cities all on its own. |
The Motley Fool
January 31, 2007
Brian Lawler |
Lilly Floats Atop Rivals The large-cap pharma posts slow, steady growth. Investors, take note. |
The Motley Fool
January 28, 2011
Brian Orelli |
Avoid This Falling Knife for Now 2011 could be just the start of a long slide for Lilly. And 2012 will see difficult year-over-year comparison. |
The Motley Fool
October 22, 2007
Brian Lawler |
Modest Numbers From Eli Lilly Its sales were up for the quarter, but a new drug might be the best indicator of its prospects. Lilly's pipeline will dictate its near-term future. |
The Motley Fool
January 28, 2010
Brian Orelli |
The Biggest Development-Stage Drugmaker, Ever Eli Lilly seems to have a lot more in common with its development-stage little brothers than it does with its big pharma brethren. |
The Motley Fool
June 30, 2010
Brian Orelli |
Is Bristol-Myers Squibb a Buy? Bristol-Myers is a better buy than Eli Lilly for one major reason: its resources. |
The Motley Fool
March 23, 2011
Brian Orelli |
Eli Lilly: Great Plan, Poor Execution Eli Lilly shuns large mergers, but hasn't produced drugs on its own. |
The Motley Fool
January 30, 2008
Brian Lawler |
Eli Lilly Is Resilient Proving that not every sector is affected by downturns, Eli Lilly released its fourth-quarter results yesterday, showing a bit of top-line growth. |
The Motley Fool
January 26, 2005
Stephen D. Simpson |
Lilly's No Wallflower The drugmaker posts tepid results as it bides time before new products hit the market. Lilly's valuation suggests that Wall Street has faith that those new drugs will come through. |
The Motley Fool
August 30, 2010
Brian Orelli |
Pipeline Checkup: Merck Has Potential The Schering-Plough acquisition has seemed to help. |
The Motley Fool
January 29, 2010
Brian Orelli |
All Grown Up, With Cash to Burn Bristol-Myers is all drugs, all the time. |
The Motley Fool
June 25, 2008
Brian Lawler |
Why the Lilly Delay, FDA? A government review of the company's top drug candidate gets pushed back. |
The Motley Fool
January 26, 2006
Stephen D. Simpson |
Will New Drugs Gild Lilly? Although Lilly's late-stage pipeline is weak, newer drugs should still be able to grow. Investors, this is still a mediocre investment option. |
The Motley Fool
September 5, 2007
Billy Fisher |
Lilly's Pipeline Continues to Produce Another schizophrenia drug from the company shows promise in a clinical trial, prompting the company to plan additional trials. This is the latest good news in what has been a good year for Lilly. |
The Motley Fool
October 7, 2008
Brian Orelli |
Eli Lilly's Risky Gamble Eli Lilly is desperate, and the high acquisition price of ImClone shows it. |
The Motley Fool
August 13, 2010
Brian Orelli |
Already a Slippery Slope for Eli Lilly The company gets a whiff of what its patent cliff might be like. |
The Motley Fool
May 31, 2007
Brian Lawler |
Dueling Fools: Eli Lilly Bear Well-managed companies don't always make for good investments. This pharmaceutical powerhouse is a good example. |
The Motley Fool
February 4, 2009
Brian Orelli |
Not If, but When, for Lilly At least Lilly now knows that it's just a matter of time until the anti-clotting agent wins FDA approval. |
The Motley Fool
October 22, 2009
Brian Orelli |
Beat Earnings, Stock Down, Rinse and Repeat For the second quarter in a row, Eli Lilly beat expectations, it raised guidance, and its stock fell for the day. |
The Motley Fool
August 12, 2011
David Williamson |
What Happened to U.S. Pharma? How did the domestic pharmaceutical industry fare in the most recent quarter? |
The Motley Fool
January 28, 2010
Brian Orelli |
Only the Strong Survive at Pfizer The culling of the pipeline isn't as bad as it sounds. |
The Motley Fool
April 19, 2004
Alyce Lomax |
Eli Lilly's Drug Dependency Competitive concerns make Cymbalta and new drugs more important than ever. |
The Motley Fool
January 29, 2009
Brian Orelli |
Lilly's in Need of a Pep Pill Eli Lilly's quarterly earnings report was pretty boring. Some drugs were up and others were down -- the end result was flat sales. |
The Motley Fool
August 19, 2009
Brian Orelli |
Them's the Breaks for Lilly The drugmaker cuts its losses after a disappointing trial on an osteoporosis drug. |
The Motley Fool
July 24, 2009
Brian Orelli |
Juicing Up the Earnings Report How did Celgene turn an earnings release that met analysts' expectations while lowering revenue guidance on one of its drugs into an 18.6% increase in share price yesterday? |
The Motley Fool
March 20, 2008
Brian Lawler |
The AIR's Knocked Out of Alkermes Drug developer Alkermes initiates a round of cost-cutting. |
The Motley Fool
June 16, 2010
Brian Orelli |
A Drop on Bad News, but It Was a Long Shot Anyway Bydureon, Amylin Pharmaceuticals and Eli Lilly's once-weekly version of their twice-daily Byetta, has been beating up other diabetes drugs in a series of head-to-head clinical trials but it will have a tough time going after the monotherapy market. |
The Motley Fool
January 5, 2010
Brian Orelli |
Lilly's Effient: Cheap Enough, for Now In order to justify the use of Effient, Eli Lilly is touting a study published in today's Circulation demonstrating the cost effectiveness of Effient over Plavix. |
The Motley Fool
July 21, 2006
Stephen D. Simpson |
Lilly Wilts Neither the valuation nor the pipeline of this pharma makes for a compelling investment case. |
The Motley Fool
December 1, 2008
Brian Orelli |
It's Wait Until Next Year for These Drugmakers Drugs from AstraZeneca and Eli Lilly face delays because of the FDA. Both plan to resubmit their applications for approval in the first half of next year, but the delays likely will have different effects on the companies. |
The Motley Fool
January 14, 2011
Brian Orelli |
Don't Have a Stroke Over Merck's Heart Drug Welcome to pharma investing. |
The Motley Fool
July 6, 2009
Brian Orelli |
Lilly Shows Us How It's Done The company announces that the Food and Drug Administration had expanded the approval of its cancer drug, Alimta, to include maintenance therapy for nonsquamous, non-small cell lung cancer. |
The Motley Fool
October 8, 2008
Brian Orelli |
Lilly Gets Off Easy The company settles marketing issues over Zyprexa with 32 states. |
The Motley Fool
December 9, 2008
Brian Orelli |
FDA Dashes Amylin Investors' Hopes Shareholders are still waiting to hear how much longer it'll be before Amylin and Eli Lilly can submit the marketing application for the once-weekly version of diabetes drug Byetta. |
The Motley Fool
November 9, 2011
Brian Orelli |
Byetta Breakup! Buying Opportunity? We all saw this coming. Amylin Pharmaceuticals and Eli Lilly decided staying together for the kids just wasn't worth it |
The Motley Fool
March 15, 2010
Brian Orelli |
FDA Says "No Way!" Market Says "Yeah, Baby!" You can have it both ways. The Food and Drug Administration's response wasn't exactly what investors in Amylin Pharmaceuticals, Eli Lilly, and Alkermes were looking for, but they'll take it. |
The Motley Fool
May 31, 2007
Ryan Fuhrmann |
Dueling Fools: Eli Lilly Bull Thanks to a couple of recent developments and a focus on research & development, the pharma giant is a worthy contender for health-care exposure in investors' portfolios. |
The Motley Fool
August 10, 2010
Jim Mueller |
3 Beaten-Down Dividend Payers A look at three companies that might deserve a spot in your portfolio. |
The Motley Fool
November 9, 2010
Brian Orelli |
Forget R&D; Buy Your Way Into Diagnostics Eli Lilly is expanding its diagnostics business by picking up privately held Avid Radiopharmaceuticals. |
The Motley Fool
April 16, 2010
Brian Orelli |
It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet. |
The Motley Fool
July 21, 2005
Stephen D. Simpson |
Tiger Lilly or Wilting Daisy? For now, Lilly seems to me to be a middle-of-the-road type of pharmaceutical stock. There are plenty of worse ideas out there, but there are better ideas, as well. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
November 5, 2010
Brian Orelli |
Better Late Than Never for Cymbalta Eli Lilly gets an expanded approval for Cymbalta. |
The Motley Fool
January 28, 2010
Brian Orelli |
The Next Amgen? Not Yet. Amylin Pharmaceuticals is in much the same situation as Amgen is in: relatively flat sales, and the potential for a nice boost from a Food and Drug Administration approval shortly. But that's where the comparison ends. |
The Motley Fool
July 22, 2009
Brian Orelli |
The Blockbuster Around the Corner Amylin Pharmaceuticals' Byetta sales are improving, but is it enough? |
